Sale of Equity Interests in Theravance Respiratory Company, LLC and Discontinued Operations - Summary of discontinued operations (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jul. 20, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jul. 26, 2022	Feb. 21, 2020
Schedule of Equity Method Investments [Line Items]
Provision for income tax expense		$ (182,362)		$ (182,868)
Total net income from discontinued operations		$ 932,654	$ 20,602	$ 961,062	$ 39,864
2035 notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)		9.50%	9.50%	9.50%	9.50%		9.50%
2033 notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)		3.25%		3.25%		3.25%
Disposed of by Sale | TRC | Royalty Pharma
Schedule of Equity Method Investments [Line Items]
Income from investment in TRC, LLC			$ 30,208	$ 53,237	$ 68,681
Transaction - related legal expenses (prior to July 20, 2022)				(5,057)
Loss on extinguishment of debt		$ (24,022)		(24,022)
Net gain from sale of equity interests in TRC,LLC	$ 1,141,100	1,141,084		1,141,084
Provision for income tax expense		(182,362)		(182,868)
Total net income from discontinued operations		932,654	20,602	961,062	39,864
Disposed of by Sale | TRC | Royalty Pharma | 2035 notes
Schedule of Equity Method Investments [Line Items]
Interest expense on 9.5% Non-recourse notes due 2035		$ (2,046)	$ (9,606)	$ (21,312)	$ (28,817)